At present there are no well-established pharmacological approaches in the management of post-cholecystectomy alkaline reactive gastritis.
Dr Luca Santarelli and his team in Rome, Italy, assessed the effect of sucralfate or rabeprazole in patients with a history of cholecystectomy and evidence of alkaline reactive gastritis.
| Sucralfate and rabeprazole therapies were both able to significantly reduce dyspeptic sympotms|
|European Journal of Gastroenterology and Hepatology|
60 dyspeptic patients with a history of cholecystectomy, evidence of abundant gastric bile reflux at endoscopy, and histological and endocsopic signs of chronic gastritis were included in the study.
Patients were randomly assigned to 1 of 3 treatment groups. Patients were given a 3 month course of sucralfate or rabeprazole, or were kept under observation fro a 3-month period.
At the end of the treatment dyspeptic symptoms and endoscopic and histological signs were re-evaluated.
Sucralfate and rabeprazole therapies were both able to significantly reduce epigastric pain, heartburn, bloating and halitosis.
Endoscopic and histological investigations revealed reduced signs of gastritis and reduced bile reflux in patients receiving sucralfate or rabeprazole.
Dr. Santarelli's team conclude. « Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis »